{"id":44312,"date":"2025-10-24T23:21:20","date_gmt":"2025-10-24T15:21:20","guid":{"rendered":"https:\/\/flcube.com\/?p=44312"},"modified":"2025-10-24T23:21:20","modified_gmt":"2025-10-24T15:21:20","slug":"ribolifes-rbd1016-earns-ema-orphan-designation-with-ribogalstar-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44312","title":{"rendered":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform"},"content":{"rendered":"\n<p>Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted <strong>Orphan Drug Designation (ODD)<\/strong> to their small\u2011interfering RNA (siRNA) candidate <strong>RBD1016<\/strong> for the treatment of <strong>Hepatitis Delta Virus (HDV)<\/strong> infection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-rbd1016-is-a-game-changer\"><strong>Why RBD1016 Is a Game\u2011Changer<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class siRNA therapy<\/strong> for a life\u2011threatening, chronically debilitating viral infection.<\/li>\n\n\n\n<li><strong>RiboGalSTAR<\/strong> \u2013 a proprietary, liver\u2011targeting delivery platform that has demonstrated superior safety, efficacy, and long\u2011acting pharmacokinetics across multiple clinical studies.<\/li>\n\n\n\n<li><strong>Phase\u202fII Momentum<\/strong> \u2013 RBD1016 is now advancing in global Phase\u202fII trials for both Hepatitis\u202fB and Hepatitis\u202fD, positioning the company to address a major unmet need in viral hepatology.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ema-orphan-drug-designation\"><strong>EMA Orphan Drug Designation<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Hepatitis Delta Virus (HDV)<\/td><\/tr><tr><td><strong>Designated Status<\/strong><\/td><td>Orphan Drug Designation (ODD)<\/td><\/tr><tr><td><strong>Prevalence Threshold<\/strong><\/td><td>&lt;\u202f5 per 10,000 EU residents<\/td><\/tr><tr><td><strong>Benefits<\/strong><\/td><td>7\u2011year market exclusivity, protocol assistance, and potential fee waivers for clinical trials in the EU.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ribolife-s-ribogalstar-platform\"><strong>RiboLife\u2019s RiboGalSTAR Platform<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Delivery<\/strong> \u2013 Optimized for hepatocyte uptake, reducing off\u2011target exposure.<\/li>\n\n\n\n<li><strong>Clinical Validation<\/strong> \u2013 Proven safety and efficacy in early\u2011phase studies for both HBV and HDV.<\/li>\n\n\n\n<li><strong>Manufacturing Readiness<\/strong> \u2013 Scalable GMP production pipeline established in Suzhou and across Europe.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\"><strong>Next Steps<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Phase\u202fII Global Trials<\/strong> \u2013 Continue enrollment in HBV and HDV cohorts, aiming for data read\u2011out in Q1\u202f2026.<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong> \u2013 Leverage EMA ODD status to streamline submissions across the EU and pursue parallel filings in the U.S. and Japan.<\/li>\n\n\n\n<li><strong>Commercial Planning<\/strong> \u2013 Engage with payers and patient groups to facilitate rapid access upon regulatory approval.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statement\"><strong>Forward\u2011Looking Statement<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44316,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[24,1725,2110,89],"class_list":["post-44312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-rare-orphan-disease-drugs","tag-ribo-life-science","tag-ribocure-pharmaceuticals","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:21:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform\",\"datePublished\":\"2025-10-24T15:21:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2407.webp\",\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"Ribo Life Science\",\"Ribocure Pharmaceuticals\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44312#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44312\",\"name\":\"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2407.webp\",\"datePublished\":\"2025-10-24T15:21:20+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44312\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2407.webp\",\"width\":1080,\"height\":608,\"caption\":\"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44312","og_locale":"en_US","og_type":"article","og_title":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform","og_description":"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.","og_url":"https:\/\/flcube.com\/?p=44312","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:21:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform","datePublished":"2025-10-24T15:21:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44312"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","keywords":["Rare \/ orphan disease drugs","Ribo Life Science","Ribocure Pharmaceuticals","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44312#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44312","url":"https:\/\/flcube.com\/?p=44312","name":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44312#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","datePublished":"2025-10-24T15:21:20+00:00","description":"Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small\u2011interfering RNA (siRNA) candidate RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44312"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44312#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","width":1080,"height":608,"caption":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RiboLife\u2019s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44312\/revisions"}],"predecessor-version":[{"id":44317,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44312\/revisions\/44317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44316"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}